Endolysins are the future against antibiotic-resistant bacteria. These enzymes, produced by bacteriophage viruses, kill bacteria by degrading the peptidoglycan layer that forms the cell wall.… Read More »Engineering a lysin by fusion of antimicrobial peptides enhances its antibacterial properties
Inflammatory bowel disease (IBD) is a term that covers different chronic inflammatory disorders of the digestive system, including Crohn’s disease and ulcerative colitis. Opportunistic microbes,… Read More »Are phages a potential treatment for inflammatory bowel disease?
From 18to 22 July, the Viruses of Microbes 2022 meeting took place in the beautiful city of Guimarães (Portugal). The conference gathers experts from all… Read More »What’s new on microbial viruses? A chronicle from Viruses of Microbes, 2022 meeting
According to new research published by eLife, it appears so. The work, led by Urszula Łapińska and Stefano Pagliara from the University of Exeter, shows… Read More »Can bacterial growth rate influence the effectiveness of antibiotics?
Although phage therapy dates back to the 1920s, the discovery of penicillin in 1928 placed antibiotics at the center of antibacterial therapies, and phages were… Read More »What is the status of Spanish legislation regarding phage therapy?
It is well known that antibiotic-resistant microbes are becoming increasingly prevalent and that traditional antibiotics cannot cope with this growing threat. In this worrisome scenario,… Read More »Are endolysins the novel antibiotics?
The toxin-antitoxin systems are a set of two closely linked genes. One encodes the “toxin”, while the other its corresponding “antitoxin” that counteracts the toxic… Read More »A new antitoxin mechanism could neutralize different toxins and protect bacteria from bacteriophages
Results of the most comprehensive analysis to date are pretty worrying. It is widely known that bacteria resistance to antibiotics and other antimicrobial drugs poses… Read More »How many deaths caused antimicrobial resistance in 2019?
Pamplona, Barcelona, 13th July 2020 – Telum Therapeutics (‘Telum’), an emerging biotechnology company that develops new treatments for infectious diseases based on the use of lytic… Read More »Telum Therapeutics raises € 4.1 million in its first round of financing to advance the development of new synthetic biology-based therapies for the treatment of infectious diseases caused by multi-resistant bacteria.
